U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

Cover of LiverTox

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

Show details

Incretin-Based Drugs

Last Update: January 3, 2018.


The incretins are gastrointestinal polypeptide hormones that act to modulate insulin secretion from pancreatic beta cells. These hormones include glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), and they are secreted from the upper gastrointestinal tract in response to feeding. They act on the pancreas, causing insulin release even before blood glucose levels are elevated. Both hormones are polypeptides that are rapidly cleared from the serum by the enzyme dipeptidyl peptidase-4 (DPP-4). The incretin pathway provides several potential targets for therapy of type 2 diabetes, the main ones being DPP-4 inhibitors and GLP-1 analogues. These incretin-based hypoglycemic agents are relatively new and they have not been implicated as common causes of drug induced liver injury. These two groups of incretin-based drugs are quite different in chemical structure, pharmacology and safety profile and are discussed separately.

Drug Class: Antidiabetic Agents

Drugs in the Subclass, Incretin-Based Drugs:


Alogliptin 850649-62-6 C18-H21-N5-O2.C7-H6-O2
Alogliptin chemical structure
Linagliptin 668270-12-0 C25-H28-N8-O2
Linagliptin Chemical Structure
Saxagliptin 945667-22-1 C18-H25-N3-O2.H2O
Saxagliptin Chemical Structure
Sitagliptin 486460-32-6 C16-H15-F6-N5-O
Sitagliptin Chemical Structure


New and Updated

Related information

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...